(Q42874872)

9 November 2017

title

Beneficial effects of olmesartan, an angiotensin II receptor type 1 antagonist, in rats with dilated cardiomyopathy (English)

1 reference

9 November 2017

author name string

Vijayakumar Sukumaran

1

1 reference

9 November 2017

Kenichi Watanabe

2

1 reference

9 November 2017

Narasimman Gurusamy

5

1 reference

9 November 2017

Meilei Ma

6

1 reference

9 November 2017

Ken'ichi Yamaguchi

7

1 reference

9 November 2017

Kenji Suzuki

8

1 reference

9 November 2017

Makoto Kodama

9

1 reference

9 November 2017

Yoshifusa Aizawa

10

1 reference

9 November 2017

Punniyakoti T. Veeraveedu

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20876084

21 July 2024

Rajarajan A. Thandavarayan

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20876084

21 July 2024

language of work or name

1 reference

27 September 2010

1 reference

full work available at URL

9 November 2017

http://www.ebmonline.org/cgi/content/abstract/235/11/1338

online access status

open access

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20876084

http://journals.sagepub.com/doi/pdf/10.1258/ebm.2010.010016

21 July 2024

1 reference

https://api.crossref.org/works/10.1258/EBM.2010.010016

http://journals.sagepub.com/doi/full-xml/10.1258/ebm.2010.010016

21 July 2024

1 reference

https://api.crossref.org/works/10.1258/EBM.2010.010016

Experimental Biology and Medicine

21 July 2024

published in

1 reference

9 November 2017

volume

235

1 reference

9 November 2017

issue

11

1 reference

9 November 2017

page(s)

1338-1346

1 reference

A novel experimental model of giant cell myocarditis induced in rats by immunization with cardiac myosin fraction

9 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2010.010016

A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2010.010016

Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2010.010016

Olmesartan, a novel AT1 antagonist, suppresses cytotoxic myocardial injury in autoimmune heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2010.010016

Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2010.010016

Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2010.010016

Additive beneficial effects of the combination of a calcium channel blocker and an angiotensin blocker on a hypertensive rat-heart failure model

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2010.010016

Olmesartan improves endothelin-induced hypertension and oxidative stress in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2010.010016

Beneficial effects of olmesartan, a novel angiotensin II receptor type 1 antagonist, upon acute autoimmune myocarditis

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2010.010016

Effects of angiotensin II infusion on the expression and function of NAD(P)H oxidase and components of nitric oxide/cGMP signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2010.010016

Angiotensin II type 1 receptor blockers

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2010.010016

Effects of angiotensin-II receptor blocker candesartan cilexetil in rats with dilated cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2010.010016

Ouabain changes arterial blood pressure and vascular reactivity to phenylephrine in L-NAME-induced hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2010.010016

Torasemide, a long-acting loop diuretic, reduces the progression of myocarditis to dilated cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2010.010016

Low dose carvedilol inhibits progression of heart failure in rats with dilated cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2010.010016

Potential contribution of a novel antifibrotic factor, hepatocyte growth factor, to prevention of myocardial fibrosis by angiotensin II blockade in cardiomyopathic hamsters

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2010.010016

Angiotensin II in rat brain comigrates with authentic angiotensin II in high pressure liquid chromatography

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2010.010016

Myocardial fibrosis: functional significance and regulatory factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2010.010016

Role of angiotensin II in altered expression of molecules responsible for coronary matrix remodeling in insulin-resistant diabetic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2010.010016

Angiotensin II and the pathophysiology of cardiovascular remodeling

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2010.010016

Angiotensin II, oxidative stress, and extracellular matrix degradation during transition to LV failure in rats with hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2010.010016

Angiotensin II receptor blockade prevents microangiopathy and preserves diastolic function in the diabetic rat heart

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2010.010016

Long-term effects of olmesartan, an Ang II receptor antagonist, on blood pressure and the renin-angiotensin-aldosterone system in hypertensive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2010.010016

Increased circulating cytokines in patients with myocarditis and cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2010.010016

Effect of the angiotensin II receptor blocker olmesartan on the development of murine acute myocarditis caused by coxsackievirus B3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2010.010016

Angiotensin AT1 receptor antagonists exert anti-inflammatory effects in spontaneously hypertensive rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2010.010016

Rat dilated cardiomyopathy after autoimmune giant cell myocarditis

21 January 2018

2

1 reference

https://api.crossref.org/works/10.1258/EBM.2010.010016

Molecular mechanisms of myocardial remodeling

21 July 2024

7

1 reference

https://api.crossref.org/works/10.1258/EBM.2010.010016

Inhibitors of angiotensin-converting enzyme prevent myointimal proliferation after vascular injury

21 July 2024

8

1 reference

https://api.crossref.org/works/10.1258/EBM.2010.010016

Effects of water deprivation on immunoreactive angiotensin II levels in plasma, cerebroventricular perfusate and hypothalamus of the rat

21 July 2024

21

1 reference

https://api.crossref.org/works/10.1258/EBM.2010.010016

Cardiovascular reviews & reports

21 July 2024

24

12

61

Weber KT

1991

1 reference

https://api.crossref.org/works/10.1258/EBM.2010.010016

Angiotensin II, transforming growth factor-beta1 and repair in the infarcted heart

21 July 2024

25

1 reference

https://api.crossref.org/works/10.1258/EBM.2010.010016

Dose-response efficacy of valsartan, a new angiotensin II receptor blocker

21 July 2024

32

1 reference

https://api.crossref.org/works/10.1258/EBM.2010.010016

Biochemical effects of losartan, a nonpeptide angiotensin II receptor antagonist, on the renin-angiotensin-aldosterone system in hypertensive patients

21 July 2024

33

1 reference

https://api.crossref.org/works/10.1258/EBM.2010.010016

Hemodynamic and humoral effects of the angiotensin II antagonist losartan in essential hypertension

21 July 2024

35

1 reference

https://api.crossref.org/works/10.1258/EBM.2010.010016

Journal of the American College of Cardiology

21 July 2024

36

21

301A

Yamagishi H

1993

1 reference

https://api.crossref.org/works/10.1258/EBM.2010.010016

Atrial natriuretic peptide elevation in congestive heart failure in the human

21 July 2024

37

1 reference

https://api.crossref.org/works/10.1258/EBM.2010.010016

Important role of local angiotensin II activity mediated via type 1 receptor in the pathogenesis of cardiovascular inflammatory changes induced by chronic blockade of nitric oxide synthesis in rats

21 July 2024

40

1 reference

https://api.crossref.org/works/10.1258/EBM.2010.010016

21 July 2024

Identifiers

1 reference

9 November 2017

1 reference